Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search
		×
			NIOSH
			NIOSH
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


The National Institute for Occupational Safety and Health (NIOSH)


Facebook
        Twitter
        LinkedIn
        Syndicate





METRIBUZIN								Related Pages
										*OSHA comments from the January 19, 1989 Final Rule on Air Contaminants Project extracted from 54FR2332 et. seq. This rule was remanded by the U.S. Circuit Court of Appeals and the limits are not currently in force.*
**CAS:** 21087-64-9; **Chemical Formula:** C8H14N4OS
OSHA has not formerly regulated exposure to metribuzin. The proposed PEL was 5 mg/m3. NIOSH (Ex. 8-47, Table N1) concurred with the proposal, and the final rule adopts this limit. The ACGIH has recommended a TLV-TWA of 5 mg/m3 for this substance. Metribuzin is a crystalline solid.
Metribuzin is a herbicide that has a low order of acutetoxicity; single exposures to high concentrations produce central nervous system depression, and repeated high doses affect the thyroid and liver function (Deutsche Forschungsgemeinschaft 1981, as cited in ACGIH 1986/Ex.1-3, p. 411). The oral LD(50) in rats has been reported to be 2000 mg/kg;in cats and rabbits, the LD(50) is as high as 500 mg/kg. A four-hour aerosol exposure at concentrations of between 860 and 892 mg/m3was tolerated by rats and mice; no skin or eye irritation was observed in rabbits. No sensitizing effects were seen in guinea pigs, and a skin application of the 70-percent wettable powder of 1000 mg/kg per day for three weeks produced no effects in rats (Deutsche Forschungsgemeinschaft 1981, as cited in ACGIH 1986/Ex. 1-3, p. 411)
Inhalation studies have shown no adverse effects in rats exposed to 31 mg/m3 of the aerosol for six hours/day, five days/week during a three-week period (Bayer 1981, as cited in ACGIH 1986/Ex. 1-3, p.411). No carcinogenic effects were observed in rats and mice fed 20, 800,or 3200 ppm for two years (Kimmerle 1982a, as cited in ACGIH 1986/Ex.1-3, p. 411). A no-effect level of 100 ppm was observed in a two-year dietary study of rats and dogs (Deutsche Forschungsgemeinschaft 1981, as cited in ACGIH 1986/Ex. 1-3, p. 411); these same investigators observed no teratogenic, embryotoxic, or reproductive effects in rats or rabbits. In Chinese hamsters and mice, no mutagenic activity was observed (Siebert and Lemperle 1974/Ex. 1-689).
No human poisonings caused by metribuzin have been reported. In oral long-term studies, the highest no-observed-effect levels (NOELs) were 2.5 to 5 mg/kg per day (ACGIH 1986/Ex. 1-3, p. 411). Singleand repeated patch tests in humans did not cause irritation orsensitization (Deutsche Forschungsgemeinschaft 1981, as cited in ACGIH 1986/Ex.1-3, p. 411). Except for NIOSH’s concurrence with this limit (Ex. 8-47,Table N1), no comments were received on metribuzin.
In the final rule, OSHA is establishing an 8-hour TWA PEL of5 mg/m3 TWA for metribuzin. The Agency concludes that this limit will protect workers against the significant risks of metabolic and central nervous system effects, which are material impairments of health that are potentially associated with workplace exposure to metribuzin at the levels permitted by the absence of any OSHA limit.
										
							
								Page last reviewed:  September 28, 2011						Content source:  	National Institute for Occupational Safety and Health NIOSH
1988 OSHA PEL Project Documentation
Index of Chemical Names
Index of CAS Numbers Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue